CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
CytoMed Therapeutics 簽署 HOA 和諒解備忘錄以推進異基因 Gamma Delta T 細胞技術的研究
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that it has entered into a Heads of Agreement (HOA) with CytoMed Therapeutics China Limited (CytoMed China), a company incorporated in Hong Kong and a Memorandum of Understanding (MOU) with BioNex Solutions Inc., 千尋生命科學.
總部位於新加坡的生物製藥公司CytoMed Therapeutics Limited（納斯達克股票代碼：GDTC）（“CytoMed” 或 “公司”）今天宣佈已與CytoMed Therapeutics China Limited（CytoMed China）簽訂協議負責人（HOA），一家在香港註冊成立的公司，與Bionex Solutions Inc. 簽訂了諒解備忘錄（MOU），千葉生命。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間